BAX · Stock research · Public disclosure research
Baxter International Inc
Data as of Jun 3, 2026. Collected disclosures, not exhaustive history.
30-day and 12-month windows end Oct 15, 2026 and use transaction dates, not disclosure dates. The data-as-of date above reflects the latest collected disclosure and may be older than the window end.
| Teaff JamesPresident, CCS | Tax withholdingNon-derivative security10b5-1 plan not indicated | 321 | $18.68 | $5,996.28 | 31,063 | Jun 2, 2026 | Jun 3, 2026SEC filing |
| Wallace Steven P.President, Adv. Surgery | Tax withholdingNon-derivative security10b5-1 plan not indicated | 153 | $18.68 | $2,858.04 | 70,128 | Jun 2, 2026 | Jun 3, 2026SEC filing |
| Zielinski Anita ASVP, Interim CFO, CAO & Cntrlr | Grant / awardNon-derivative security10b5-1 plan not indicated | 13,426 | — | — | 59,714 | Jun 1, 2026 | Jun 3, 2026SEC filing |
| Ampofo William A. IIDirector | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 30,375 | May 5, 2026 | May 7, 2026SEC filing |
| Craig Jeffrey ADirector | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 23,662 | May 5, 2026 | May 7, 2026SEC filing |
| McDonnell Michael R.Director | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 14,647 | May 5, 2026 | May 7, 2026SEC filing |
| Shafer David BrentDirector, Chair of the Board | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 72,804 | May 5, 2026 | May 7, 2026SEC filing |
| MORRISON PATRICIADirector | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 42,386 | May 5, 2026 | May 7, 2026SEC filing |
| SCHLICHTING NANCY MDirector | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 34,994 | May 5, 2026 | May 7, 2026SEC filing |
| Wendell Amy McBrideDirector | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 44,235 | May 5, 2026 | May 7, 2026SEC filing |
| Wilkes David S.Director | Grant / awardNon-derivative security10b5-1 plan not indicated | 12,836 | — | — | 37,076 | May 5, 2026 | May 7, 2026SEC filing |
| Grade Joel T.EVP and CFO | Tax withholdingNon-derivative security10b5-1 plan not indicated | 8,153 | $17.69 | $144,226.57 | 271,674 | Mar 6, 2026 | Mar 10, 2026SEC filing |
| Rasul ReazurEVP,Group Pres,Healthcare | Tax withholdingNon-derivative security10b5-1 plan not indicated | 12,674 | $17.69 | $224,203.06 | 125,557 | Mar 6, 2026 | Mar 10, 2026SEC filing |
| Rosenbloom David S.EVP and General Counsel | Tax withholdingNon-derivative security10b5-1 plan not indicated | 6,620 | $17.69 | $117,107.80 | 138,216 | Mar 6, 2026 | Mar 10, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Tax withholdingNon-derivative security10b5-1 plan not indicated | 2,848 | $17.69 | $50,381.12 | 75,045 | Mar 6, 2026 | Mar 10, 2026SEC filing |
| Zielinski Anita ASVP, CAO and Controller | Tax withholdingNon-derivative security10b5-1 plan not indicated | 1,932 | $17.69 | $34,177.08 | 46,281 | Mar 6, 2026 | Mar 10, 2026SEC filing |
| Rosenbloom David S.EVP and General Counsel | Tax withholdingNon-derivative security10b5-1 plan not indicated | 1,336 | $19.69 | $26,305.84 | 144,837 | Mar 2, 2026 | Mar 3, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Tax withholdingNon-derivative security10b5-1 plan not indicated | 1,852 | $19.69 | $36,465.88 | 77,894 | Mar 2, 2026 | Mar 3, 2026SEC filing |
| Rasul ReazurEVP,Group Pres,Healthcare | Tax withholdingNon-derivative security10b5-1 plan not indicated | 1,614 | $19.69 | $31,779.66 | 138,231 | Mar 2, 2026 | Mar 3, 2026SEC filing |
| Zielinski Anita ASVP, CAO and Controller | Grant / awardNon-derivative security10b5-1 plan not indicated | 30,864 | — | — | 48,214 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Grade Joel T.EVP and CFO | Grant / awardNon-derivative security10b5-1 plan not indicated | 42,735 | — | — | 279,828 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Grade Joel T.EVP and CFO | Grant / awardDerivative security10b5-1 plan not indicated | 103,448 | — | — | 103,448 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Rosenbloom David S.EVP and General Counsel | Grant / awardNon-derivative security10b5-1 plan not indicated | 26,709 | — | — | 146,173 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Rosenbloom David S.EVP and General Counsel | Grant / awardDerivative security10b5-1 plan not indicated | 64,655 | — | — | 64,655 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Grant / awardNon-derivative security10b5-1 plan not indicated | 23,742 | — | — | 79,748 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Grant / awardDerivative security10b5-1 plan not indicated | 57,471 | — | — | 57,471 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Carlisle CynthiaExecutive Vice President, CHRO | Grant / awardNon-derivative security10b5-1 plan not indicated | 17,806 | — | — | 17,806 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Carlisle CynthiaExecutive Vice President, CHRO | Grant / awardNon-derivative security10b5-1 plan not indicated | 11,871 | — | — | 29,677 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Carlisle CynthiaExecutive Vice President, CHRO | Grant / awardDerivative security10b5-1 plan not indicated | 43,103 | — | — | 43,103 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Hider Andrew P.President and CEO, Director | Grant / awardNon-derivative security10b5-1 plan not indicated | 201,804 | — | — | 572,239 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Hider Andrew P.President and CEO, Director | Grant / awardDerivative security10b5-1 plan not indicated | 488,506 | — | — | 488,506 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| McDonnell Michael R.Director | Grant / awardNon-derivative security10b5-1 plan not indicated | 1,811 | — | — | 1,811 | Feb 13, 2026 | Feb 18, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Grant / awardNon-derivative security10b5-1 plan not indicated | 2,273 | — | — | 56,924 | Feb 9, 2026 | Feb 11, 2026SEC filing |
| Soriano Maria CeciliaGroup Pres., ITT & Pharma. | Tax withholdingNon-derivative security10b5-1 plan not indicated | 918 | $21.73 | $19,948.14 | 56,006 | Feb 9, 2026 | Feb 11, 2026SEC filing |
Review the entire collected insider disclosure history with a free account.
Full collected history is available here after sign-in, separate from the public 12-month window. It is not an exhaustive trading history.
0 public-window transactions explicitly indicate a 10b5-1 plan. A missing indication is not proof that a transaction was discretionary. Prices and values are shown only when reported; unavailable fields are not filled with zero.
Collected disclosures show 0 open-market purchases and 0 sales with transaction dates in the trailing 30 days ending Oct 15, 2026. Net reported purchase less sale value is $0.00. The latest collected disclosure data is as of Jun 3, 2026. These counts do not represent every insider action.
0 distinct insiders appear in collected disclosures for transaction dates in the trailing 30 days ending Oct 15, 2026. The latest collected Form 4 was filed on Jun 3, 2026. A filing date is not the transaction date.
This page shows 34 collected transactions dated in the trailing 12 months ending Oct 15, 2026. 0 older collected transactions are summarized outside this window and can be viewed here after sign-in. This is collected disclosure coverage, not exhaustive history; 10b5-1 plan status and derivative securities are labeled per record.
Insider data covers the trailing 12 months on public tables. Congressional tables cover all saved disclosures. Neither is an exhaustive history. Form 4 filing dates and congressional disclosure dates may differ from trade dates. Congressional amounts are ranges, not estimated dollar totals. Disclosure activity alone does not establish intent or predict returns.
From disclosure to research
Create a workspace for filing analysis and research notes. Filing-alert availability depends on your plan. Review the plan features separately; opening the plans page does not create an alert.